No abstract

The present review article confirms the importance of nanopharmaceuticals and impart the knowledge for making the significant approaches and strategies to overcome the manufacturing, safety, legal and regulatory issues related to nanopharmaceuticals.

Efficacious management of malocclusion following maxillofacial trauma requires understanding of the interaction between teeth and alveolar bone, facial skeleton, temporomandibular joints, and facial neuromusculature. Success is best achieved with a multidisciplinary approach. This article describes the management of malocclusion after primary repair by highlighting important clinical features and offering guidelines for secondary repair through revision surgical reduction, prosthodontic rehabilitation, orthodontic therapy, restorative dentistry, and orthognathic surgery.

Bruxism is the non-functional clenching or grinding of the teeth that may occur during sleep or, less commonly in the daytime in 5-20% of adults and about 30% of 56 year old children. Although research on bruxism is extensive, its etiology remains debatable. There is some literature to suggest that bruxism is correlated with temporomandibular disorders (TMDs) and malocclusion. The aim of this article is to present the course of this condition in a case of bruxism coupled with TMD with special emphasis on the importance of accurate diagnosis of maxillofacial pain. We also report an association between supernumerary teeth and TMDs that has not been reported earlier in the literature.

Introduction:The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy.Methods: In this phase III, open-label, multicenter study, 254 adults with stable CAD having uncontrolled hypertension despite being treated with FDC of metoprolol (25/50 mg) and telmisartan (40 mg) were included. Patients received either of the following FDC for 24 weeks: metoprolol (25 mg), telmisartan (40 mg), and chlorthalidone (12.5 mg) (FDC1; n = 139) or metoprolol (50 mg), telmisartan (40 mg), and chlorthalidone (12.5 mg) (FDC2; n = 115) tablets once daily. The FDCs were developed using the novel Wrap Matrix TM